Subscribe to RSS
DOI: 10.1055/s-0029-1245934
© Georg Thieme Verlag KG Stuttgart · New York
Efficacy of Contrast-Enhanced US versus CT or MRI for the Therapeutic Control of Percutaneous Radiofrequency Ablation in the Case of Hepatic Malignancies
Aussagekraft der kontrastmittelverstärkten Sonografie im Vergleich mit CT oder MR in der Kontrolle nach perkutaner Radiofrequenzablation von LebertumorenPublication History
received: 14.4.2010
accepted: 18.11.2010
Publication Date:
11 January 2011 (online)

Zusammenfassung
Ziel: Zur Beurteilung der Aussagekraft kontrastmittelunterstützter Verfahren nach Radiofrequenzablationen (RFA) wurden Patienten mit malignen Lebertumoren nach RFA mit kontrastmittelverstärktem Ultraschall (CEUS), Computertomografie (CT) und Magnetresonanztomografie (MRI) verlaufskontrolliert und die Ergebnisse miteinander verglichen. Material und Methoden: Analysiert wurden über einen Zeitraum von 7 Jahren 194 RFAs von 76 Patienten mit 118 Raumforderungen der Leber (n = 55 HCC, n = 63 Metastasen), die mit Bildgebung (CEUS und CT/MRI) im Verlauf (Goldstandard zur Diagnosestellung) untersucht wurden. Kriterien für ein Rezidiv waren eine KM-Anreicherung im Bereich der behandelten Raumforderung von mehr als 5 mm und Größenwachstum von mind. 25 % im Follow-up. Ergebnisse: Vergleichsgruppe CEUS-CT: Von insgesamt 65 Vergleichsuntersuchungen stimmten die Befunde in 54 Fällen (83,1 %) überein. In 7 Fällen (10,8 %) wurde die korrekte Diagnose nur im CEUS gestellt, in 2 Fällen (3,1 %) nur im CECT. In 2 Fällen (3,1 %) lieferten beide Verfahren falsche Ergebnisse. Korrektklassifikationsrate (DA): CEUS 93,8 %, CT 86,2 %. Vergleichsgruppe CEUS-MRI: Von insgesamt 26 Vergleichsuntersuchungen stimmten CEUS und MRI in 23 Fällen bzw. 88,5 % überein. In den 3 diskordanten Fällen (11,5 %) wurde die korrekte Diagnose nur im CEUS gestellt. DA (n = 26): CEUS 100 %, MRI 88,4 %. Schlussfolgerung: Im Follow-up von Tumorbehandlungen der Leber ist CEUS der CT und der MRI ebenbürtig.
Abstract
Purpose: The goal of this study was to assess the informative value of contrast-enhanced ultrasound after radiofrequency ablation (RFA). Patients who had undergone RFA of malignant liver tumors were followed up with contrast-enhanced sonography (CEUS), computed tomography (CT) and/or magnetic resonance tomography (MRI), and the outcomes were compared. Materials and Methods: 76 patients undergoing 194 RFAs for 118 hepatic neoplasms (n = 55 HCC, n = 63 metastases) in the course of a 7-year period were examined post-interventionally using CEUS and CT or MRI. During follow-up (gold standard of evaluation), contrast agent rim accumulations with a diameter greater than 5 mm and a growth rate of at least 25 % were counted as a recurrence. Results: CEUS-CT comparison group: A total of 65 scan pairs were compared. In 54 cases (83.1 %) the findings were the same with either method. In 7 cases (10.8 %) CEUS confirmed the correct diagnosis, and in 2 cases (3.1 %) only CT was correct. In 2 cases (3.1 %) both methods yielded incorrect results. Diagnostic accuracy (DA): CEUS 93.8 %, CT 86.2 %. CEUS-MRI comparison group: In 23 cases (88.5 %) of a total of 26 scan pairs, the findings were the same for both CEUS and MRI. In 3 discordant cases only CEUS confirmed the correct diagnosis (3 cases, 11.5 %). Diagnostic accuracy DA (n = 26): CEUS 100 %, MRI 88.4 %. Conclusion: CEUS performs equally to CT and MRI in the follow-up of patients treated for liver tumors by RFA.
Key words
abdomen - ablation procedures - contrast agents
References
- 1
Spangenberg H C, Thimme R, Blum H E.
Evolving therapies in the treatment of hepatocellular carcinoma.
Biologics.
2008;
2
453-462
MissingFormLabel
- 2
El-Serag H B, Marrero J A, Rudolph L et al.
Diagnosis and treatment of hepatocellular carcinoma.
Gastroenterology.
2008;
134
1752-1763
MissingFormLabel
- 3
Lau W Y, Lai E C.
Hepatocellular carcinoma: current management and recent advances.
Hepatobiliary Pancreat Dis Int.
2008;
7
237-257
MissingFormLabel
- 4
Abdalla E K, Vauthey J N, Ellis L M et al.
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and
combined resection/ablation for colorectal liver metastases.
Ann Surg.
2004;
239
818-825
; discussion 825 – 827
MissingFormLabel
- 5
Abdel-Misih S R, Schmidt C R, Bloomston P M.
Update and review of the multidisciplinary management of stage IV colorectal cancer
with liver metastases.
World J Surg Oncol.
2009;
7
72
MissingFormLabel
- 6
Guan Y S, Sun L, Zhou X P et al.
Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up.
World J Gastroenterol.
2004;
10 (24)
3543-3548
MissingFormLabel
- 7
Goldberg S N, Grassi C J, Cardella J F et al.
Image-guided tumor ablation: standardization of terminology and reporting criteria.
Radiology.
2005;
235
728-739
Epub 2005 Apr 21. Review
MissingFormLabel
- 8
Couinaud C.
Segmental and lobar left hepatectomies, studies on anatomical conditions.
J Chir.
1952;
68
697-715
MissingFormLabel
- 9
EFSUMB Study Group .
Guidelines for the use of contrast agents in ultrasound.
Ultraschall in Med.
2004;
25
249-256
MissingFormLabel
- 10
Claudon M, Cosgrove D, Albrecht T et al.
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound
(CEUS) – update 2008.
Ultraschall in Med.
2008;
29
28-44
MissingFormLabel
- 11
Strobel D, Seitz K, Blank W et al.
Contrast-enhanced ultrasound for the characterization of focal liver lesions – diagnostic
accuracy in clinical practice (DEGUM multicenter trial).
Ultraschall in Med.
2008;
29
499-505
MissingFormLabel
- 12
Strobel D, Seitz K, Blank W et al.
Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma,
hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver
lesions in contrast-enhanced ultrasound (CEUS).
Ultraschall in Med.
2009;
30
376-382
Epub 2009 Aug 17
MissingFormLabel
- 13
Seitz K, Strobel D, Bernatik T et al.
Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions
– prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial).
Parts of this manuscript were presented at the Ultrasound Dreiländertreffen 2008,
Davos.
Ultraschall in Med.
2009;
30
383-389
Epub 2009 Aug 17
MissingFormLabel
- 14
Choi D, Lim H K, Lee W J et al.
Radiofrequency ablation of liver cancer: early evaluation of therapeutic response
with contrast-enhanced ultrasonography.
Korean J Radiol.
2004;
5
185-198
MissingFormLabel
- 15
Lu M D, Yu X L, Li A H et al.
Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring
percutaneous thermal ablation procedure in patients with hepatocellular carcinoma:
a multi-center study in China.
Ultrasound Med Biol.
2007;
33 (11)
1736-1749
Epub 2007 Jul 16
MissingFormLabel
- 16
Shimizu M, Iijima H, Horibe T et al.
Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection
Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with
radio-frequency ablation therapy.
Hepatol Res.
2004;
29
235-242
MissingFormLabel
- 17
Imai Y, Okamoto N, Tateiwa N et al.
Assessment of treatment efficacy in radiofrequency ablation for hepatocellular carcinoma:
Comparison between multiplanar reconstruction by multi-detector row CT and contrast-enhanced
ultrasonography by Truagent detection mode.
Hepatol Res.
2006;
35
69-75.
Epub 2006 Mar 10
MissingFormLabel
- 18
Kim C K, Choi D, Lim H K et al.
Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular
carcinoma: utility of contrast-enhanced agent detection imaging.
Eur J Radiol.
2005;
56
66-73
MissingFormLabel
- 19
Solbiati L, Ierace T, Tonolini M et al.
Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced
ultrasound.
Eur J Radiol.
2004;
51
S19-S23
MissingFormLabel
- 20
Meloni M F, Livraghi T, Filice C et al.
Radiofrequency ablation of liver tumors: the role of microbubble ultrasound contrast
agents.
Ultrasound Q.
2006;
22
41-47
MissingFormLabel
- 21
Ricci P, Cantisani V, Drudi F et al.
Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome
of radiofrequency ablation in hepatocellular carcinoma?.
Ultraschall in Med.
2009;
30
252-258
Epub 2009 Mar 11
MissingFormLabel
- 22
Vogt F M, Antoch G, Veit P et al.
Morphologic and functional changes in nontumorous liver tissue after radiofrequency
ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
J Nucl Med.
2007;
48
1836-1844.
Epub 2007 Oct 17
MissingFormLabel
- 23
Schraml C, Clasen S, Schwenzer N F et al.
Diagnostic performance of contrast-enhanced computed tomography in the immediate assessment
of radiofrequency ablation success in colorectal liver metastases.
Abdom Imaging.
2008;
33
643-651
MissingFormLabel
- 24
Kim S K, Lim H K, Kim Y H et al.
Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging
findings.
Radiographics.
2003;
23
107-121
MissingFormLabel
Dr. Markus Frieser
Department of Medicine I, NOZ
Ulmenweg 18
91054 Erlangen
Germany
Phone: ++ 49/91 31/8 53 50 00
Fax: ++ 49/91 31/8 53 52 52
Email: markus.frieser@uk-erlangen.de